Polyganics
Polyganics, a Netherlands-based medical technology firm founded in 1999 and now part of Regenity Biosciences, develops proprietary synthetic polymer bioresorbable devices for nerve, dural, spine, orthopedic, and dental tissue regeneration, selling branded products and CDMO services to medical device OEMs across 80+ countries.
- Company typePrivate
- Founded1999
- HeadquartersGroningen, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Polyganics does
Polyganics is a Netherlands-based medical technology company, founded in 1999 and headquartered in Groningen, that develops, manufactures, and markets bioresorbable medical devices built on proprietary synthetic polymer chemistry. Its portfolio spans nerve repair, dural repair and closure, spine and orthopedics (including the RejuvaKnee™ regenerative meniscus implant), and dental regeneration products, designed as structural scaffolds that degrade as the body heals to enable permanent functional tissue restoration.
In 2022, Polyganics was acquired by Collagen Matrix, Inc., a 1997-founded pioneer in xenograft-based bioresorbable devices, which subsequently rebranded as Regenity Biosciences. The combined entity now operates from Paramus, NJ (HQ) and Allendale, NJ (new facility leased April 2026), with Polyganics functioning as the synthetic-polymer arm of a unified bioresorbable platform spanning collagen and polymer chemistry. The business monetizes through three streams: branded and private-label bioresorbable device sales (30M+ cumulative patients impacted), contract development and manufacturing (CDMO) services for medical device partners (5M+ devices produced annually, ISO 13485/MDSAP-certified and FDA-registered facilities), and collaborative/co-development licensing engagements leveraging a deep predicate device library. Notable commercial partnerships include GT Medical Technologies (GammaTile brain-tumor therapy, fast-tracked via 510(k)), with the combined enterprise supported by 170+ regulatory approvals worldwide and a distribution footprint in 80+ countries.
The company is privately held as a wholly-owned subsidiary of Regenity Biosciences, which is itself backed by private equity sponsors Linden Capital Partners (legacy investor) and Cinven (strategic investment, February 2026). It has 11–50 employees, sells through a hybrid direct enterprise sales motion and a global distributor/channel network, and does not publicly disclose pricing or revenue. Recent strategic activity is dominated by FDA 510(k) clearance and commercial launch of RejuvaKnee™, NMPA approval in China for dental products, the 2025 R&D 100 Award, the Cinven investment, and a new Allendale campus — all signaling an active commercial scaling phase.
Polyganics firmographics
Firmographics- Name
- Polyganics
- Legal name
- Polyganics
- Website
- https://polyganics.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Polyganics, a Netherlands-based medical technology firm founded in 1999 and now part of Regenity Biosciences, develops proprietary synthetic polymer bioresorbable devices for nerve, dural, spine, orthopedic, and dental tissue regeneration, selling branded products and CDMO services to medical device OEMs across 80+ countries.
- Ownership category
- akta.pro rank
Polyganics industry classification
Industry- Product category
- Regenerative Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Miscellaneous Plastics Products (3080), Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821)
- akta.pro primary industry
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
- akta.pro secondary industry
- Cell Therapy CDMO (HLAGABAD)
Keywords
Where Polyganics is headquartered
LocationHeadquarters
- HQ city
- Groningen
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Polyganics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Private-label and branded product sales: Sale of proprietary and white-label bioresorbable medical devices (nerve repair, dural repair, spine/orthopedics, dental) to medical device partners and distributors worldwide. 30M+ medical devices sold cumulatively.
- CDMO services revenue: Contract development and manufacturing organization (CDMO) services — design, development, regulatory support, and precision manufacturing for partner companies developing regenerative therapies. Examples include support for GT Medical Technologies' GammaTile FDA submission.
- Collaborative/co-development licensing: Customized collaborative product development engagements leveraging proprietary bioresorbable technology platforms and design asset library; partners co-create novel regenerative devices for rapid path-to-market.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Polyganics product offering
Product offeringCore offering
Polyganics develops, manufactures, and markets bioresorbable medical devices based on synthetic polymer chemistry for tissue regeneration across nerve repair, dural repair, spine/orthopedic, and dental applications. Following its 2022 acquisition by Collagen Matrix (now Regenity Biosciences), the portfolio also serves as the foundation for end-to-end Contract Development and Manufacturing Organization (CDMO) services delivered to medical device partners worldwide.
Product overview
Polyganics was a leading medical technology company specializing in synthetic polymer bioresorbable devices and was acquired in 2022 by Collagen Matrix, Inc., which subsequently rebranded as Regenity Biosciences. Today, Polyganics' synthetic polymer portfolio sits alongside Regenity's legacy collagen (xenograft-based) offerings as part of a unified bioresorbable platform architecture. The combined offering is organized into therapeutic-area modules — Dental, Dural Repair & Closure, Spine & Orthopedics (including the RejuvaKnee™ meniscal repair device), and Nerve Repair — and is underpinned by proprietary Technology Platforms in collagen and synthetic polymer chemistry. Regenity also operates CDMO Services (Contract Development & Manufacturing), enabling partners to leverage the same bioresorbable expertise, design asset library, and FDA-registered, ISO 13485 / MDSAP-certified manufacturing infrastructure for private-label and co-developed regenerative medical devices. Notable highlights include 30+ million patients impacted, 170+ regulatory approvals worldwide, partners in 80+ countries, and 5M+ regenerative medical devices produced annually.
Differentiator
Problem solved
Functional benefit
Products and services
- RejuvaKnee™
- Dental Product Portfolio
- Dural Repair & Closure Portfolio
- Spine & Orthopedics Portfolio
- Nerve Repair Portfolio
- CDMO Services
Companies that use Polyganics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Polyganics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Polyganics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- GT Medical TechnologiescorePartnered with Regenity Biosciences (parent of Polyganics) to develop and manufacture GammaTile, a breakthrough in brain tumor treatment. Regenity's predicate technology enabled GT Medical Technologies to obtain 510(k) approval very quickly. Featured in 'Behind the Innovation' partner testimonial video series.
- Geistlich (reference comparator)minorGeistlich Bio-Gide® collagen membrane was used as the comparator in Regenity's multicenter clinical study for its novel crosslinked collagen membrane in China. Not a commercial partnership — referenced as a benchmark.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Polyganics competitors and assessment
Company assessmentBroad incumbents
- Stryker: Global orthopedics and medical devices leader with a large sports medicine franchise (relevant to RejuvaKnee™). Competes indirectly with Polyganics/Regenity in spine, orthopedics, and regenerative solutions at far greater scale.
- Medtronic: Largest pure-play medical device company with spinal, cranial, neurological, and surgical franchises that overlap with Polyganics' dural repair, spine, and nerve repair portfolios. Operates as a broad incumbent with far greater scale.
- Smith+Nephew: Global medical device company with sports medicine, orthopedics, and advanced wound management franchises — overlapping with Polyganics/Regenity's orthopedic, dental, and wound-care-adjacent regenerative portfolio.
- Integra LifeSciences: Diversified medical device company with strong positions in neurosurgery (dural repair — direct overlap with Polyganics), regenerative technologies, and orthopedics. A broad incumbent offering overlapping capabilities in multiple Polyganics therapeutic areas.
Direct peers
- Tissue Regenix Group: UK-based regenerative medicine company developing bioresorbable scaffolds (dCELL®) for soft tissue repair including orthopedic and dental applications — directly comparable product modality to Polyganics' bioresorbable scaffolds.
- MTF Biologics: Non-profit tissue bank and regenerative medicine organization providing allograft and biologic devices plus CDMO-style services to medtech partners. Comparable to Polyganics/Regenity in regenerative CDMO services and tissue-repair product portfolio.
- DSM Biomedical (dsm-firmenich): Biomaterials business supplying bioresorbable polymers and regenerative materials to medical device manufacturers — directly comparable to Polyganics' synthetic polymer bioresorbable CDMO platform and a competitor for OEM material supply contracts.
- Geistlich Pharma: Swiss-headquartered leader in collagen-based regenerative dental membranes (Bio-Gide®) and bone substitutes. Geistlich is the named comparator product in Polyganics/Regenity's China dental clinical study and directly competes in dental regeneration and orthobiologics.
Emerging players
- Cerapedics: Commercial-stage orthobiologics company focused on bone regeneration in spine surgery (i-FACTOR). Competes with Polyganics/Regenity in the spine regenerative category at a smaller, more specialized scale.
- Xtant Medical: US-focused regenerative medicine company marketing orthobiologic and spinal implant products. Comparable to Polyganics/Regenity in regenerative orthopedics/spine at a smaller scale and narrower geographic footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Polyganics social profiles
Digital presencePolyganics compliance and trust
Trust signalCompliance3 records
Polyganics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Polyganics leadership team
Management profileNumber of profiles
Profiles5 records
Polyganics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Polyganics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Polyganics
What does Polyganics do?
Polyganics develops, manufactures, and markets bioresorbable medical devices based on synthetic polymer chemistry for tissue regeneration across nerve repair, dural repair, spine/orthopedic, and dental applications. Following its 2022 acquisition by Collagen Matrix (now Regenity Biosciences), the portfolio also serves as the foundation for end-to-end Contract Development and Manufacturing Organization (CDMO) services delivered to medical device partners worldwide.
Is Polyganics a public or private company?
Polyganics is a private company. It is classified as private equity controlled and is currently acquired.
When was Polyganics founded?
Polyganics was founded in 1999. It employs 11 to 50 people.
Where is Polyganics based?
Polyganics is headquartered in Groningen, Netherlands, in the Europe region.
How does Polyganics make money?
Three revenue lines are on record. Private-label and branded product sales are the primary driver. The others are CDMO services revenue and collaborative/co-development licensing.
Who are Polyganics's main competitors?
Broad incumbents on record are Stryker, Medtronic, Smith+Nephew and Integra LifeSciences. Direct peers are Tissue Regenix Group, MTF Biologics, DSM Biomedical (dsm-firmenich) and Geistlich Pharma. Emerging players are Cerapedics and Xtant Medical.
Does Polyganics have an API?
No public API is recorded for Polyganics.
What industry is Polyganics in?
Polyganics's product category is Regenerative Medical Devices. Its primary akta.pro industry code is HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO, with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 339112 and its SIC code is 3842.